236 related articles for article (PubMed ID: 25758812)
1. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
Hsu CH; Lober RM; Li MD; Partap S; Murphy PA; Barnes PD; Fisher PG; Yeom KW
J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
[TBL] [Abstract][Full Text] [Related]
2. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
[TBL] [Abstract][Full Text] [Related]
3. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
[TBL] [Abstract][Full Text] [Related]
4. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker.
Jain R; Scarpace LM; Ellika S; Torcuator R; Schultz LR; Hearshen D; Mikkelsen T
J Neurooncol; 2010 Feb; 96(3):423-31. PubMed ID: 19859666
[TBL] [Abstract][Full Text] [Related]
5. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
Ringelstein A; Turowski B; Gizewski ER; Schroeteler J; Rapp M; Saleh A; Lanzman RS; Mathys C; Sabel M; Mödder U
Rofo; 2010 Oct; 182(10):868-72. PubMed ID: 20740393
[TBL] [Abstract][Full Text] [Related]
7. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
8. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.
Rahm V; Boxheimer L; Bruehlmeier M; Berberat J; Nitzsche EU; Remonda L; Roelcke U
J Nucl Med; 2014 Apr; 55(4):546-50. PubMed ID: 24566001
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.
Rieger J; Bähr O; Müller K; Franz K; Steinbach J; Hattingen E
J Neurooncol; 2010 Aug; 99(1):49-56. PubMed ID: 20035366
[TBL] [Abstract][Full Text] [Related]
10. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas.
Foster KA; Ares WJ; Pollack IF; Jakacki RI
Pediatr Blood Cancer; 2015 Feb; 62(2):240-245. PubMed ID: 25382690
[TBL] [Abstract][Full Text] [Related]
12. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.
Nowosielski M; Recheis W; Goebel G; Güler O; Tinkhauser G; Kostron H; Schocke M; Gotwald T; Stockhammer G; Hutterer M
Neuroradiology; 2011 Apr; 53(4):291-302. PubMed ID: 21125399
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
Kothari P; White NS; Farid N; Chung R; Kuperman JM; Girard HM; Shankaranarayanan A; Kesari S; McDonald CR; Dale AM
AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
[TBL] [Abstract][Full Text] [Related]
14. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Kalra M; Heath JA; Kellie SJ; Dalla Pozza L; Stevens MM; Swamy S; McCowage GB
J Pediatr Hematol Oncol; 2015 Aug; 37(6):e341-6. PubMed ID: 26056795
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
[TBL] [Abstract][Full Text] [Related]
16. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.
Barajas RF; Butowski NA; Phillips JJ; Aghi MK; Berger MS; Chang SM; Cha S
Acad Radiol; 2016 Sep; 23(9):1073-82. PubMed ID: 27443507
[TBL] [Abstract][Full Text] [Related]
17. Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).
Farid N; Almeida-Freitas DB; White NS; McDonald CR; Kuperman JM; Almutairi AA; Muller KA; VandenBerg SR; Kesari S; Dale AM
J Neurooncol; 2014 Dec; 120(3):539-46. PubMed ID: 25135423
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
19. Diffusion restriction associated with bevacizumab treatment in recurrent glial tumors, evaluation of survival with ADC measurement analysis.
Savran B; Göç MF; Öztürk FU; Duran AO; Ünal Ö
Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4153-4161. PubMed ID: 37203841
[TBL] [Abstract][Full Text] [Related]
20. ADC texture--an imaging biomarker for high-grade glioma?
Brynolfsson P; Nilsson D; Henriksson R; Hauksson J; Karlsson M; Garpebring A; Birgander R; Trygg J; Nyholm T; Asklund T
Med Phys; 2014 Oct; 41(10):101903. PubMed ID: 25281955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
